December 08, 2016 12:12 PM ET

Pharmaceuticals

Company Overview of Taiho Pharmaceutical Co., Ltd.

Company Overview

Taiho Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products. Its products include S-1, an oral antimetabolite and a combination of pharmacological compounds; ABI-007(Abraxane, a human serum albumin-bound paclitaxel; TSU-68, an orally administered, small-molecule, multiple receptor tyrosine kinase inhibitor; TAS-102, a novel combination antitumor agent; TAS-118, an antimetabolite solution; and ET-743(trabectedine), a synthetic derivative of a substance extracted from the colonial tunicate ecteinascidia turbinata. The company’s products also comprise TAS-114, an inhibitor of dUTPase, a gatekeeper protein in pyrimidine-metabolism; TAS-115, an ATP-competi...

1-27 Kandanishiki-cho

Chiyoda-ku

Tokyo,  101-8444

Japan

Founded in 1963

Phone:

81 3 3294 4527

Fax:

81 3 3233 4057

Key Executives for Taiho Pharmaceutical Co., Ltd.

President and Representative Director
Chief Executive Officer of Otsuka Holdings Co., Ltd., President of Otsuka Holdings Co., Ltd. and Representative Director of Otsuka Holdings Co., Ltd.
Age: 66
Head of Production Division - Cmc Center and Director
Compensation as of Fiscal Year 2016.

Taiho Pharmaceutical Co., Ltd. Key Developments

Taiho Pharmaceutical Co., Ltd. Announces Establishment of Taiho Ventures, LLC

Taiho Pharmaceutical Co., Ltd. announced on May 10 that it has established Taiho Ventures, LLC, a strategic corporate venture capital arm of TPC, in California, USA. Taiho Ventures will be investing globally in the start-up companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. With the support of Taiho's established expertise in the field of oncology product discovery and development, Taiho Ventures will provide financial resources and company outreach to build strategic alliances to help translate novel research and high-potential drug candidates into cornerstone products. Initially, Taiho Ventures will make investments from the pooled amount of $50 million.

Taiho Pharmaceutical Co., Ltd. Wins European Commission Approval for Marketing Authorization for LONSURF

Taiho Pharmaceutical Co., Ltd. of Tokyo announced on April 28, 2016, that the European Commission (EC) has granted marketing authorization for LONSURF (R) (trifluridine/tipiracil), formerly known as TAS-102, in the European Union (EU) for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents. LONSURF is an oral anticancer drug, comprising the combination of trifluridine (FTD) and tipiracil (TPI), whose dual mechanism of action is designed to maintain clinical activity. LONSURF was originally developed by Taiho Pharmaceutical, and Servier will co-develop and commercialize LONSURF in EU countries under a license agreement with Taiho Pharmaceutical.

Taiho Pharmaceutical Co., Ltd. Announces Nutritive Drink Tiovita 3000

Taiho Pharmaceutical Co., Ltd. announced that it will release the nutritive drink Tiovita 3000 in Hong Kong on April 21, 2016. Tiovita 3000 is a newly developed product based on Tiovita Drink (designated quasidrug), which was originally launched in 1964 in Japan. The new product features a localized taste with a fresh grape flavor and label designed to meet consumer preferences in Hong Kong. It contains several nutritious ingredients, such as taurine, which is known for helping to heal fatigue, and more B vitamins than were in the original Tiovita Drink.

Similar Private Companies By Industry

Company Name Region
ABsize Inc. Asia
AccuRna, Inc. Asia
ACE Japan, L.L.C. Asia
AIP Corporation Asia
alphaGEN Co., Ltd. Asia

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Taiho Pharmaceutical Co., Ltd., please visit www.taiho.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.